All‐cause mortality, neonates, standard polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in all‐cause mortality, neonates, standard polyclonal IVIG compared with placebo or no intervention (moderate certainty).
2 findings from 1 review
All‐cause mortality, neonates, IgM‐enriched polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in all‐cause mortality, neonates, IgM‐enriched polyclonal IVIG compared with placebo or no intervention (low certainty).
1 finding from 1 review
28‐Day all cause mortality (adult studies) · adult patients with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) probably leads to lower all‐cause mortality, adults, standard polyclonal IVIG compared with placebo or no intervention (moderate certainty).
5 findings from 1 review
RR 0.81 [0.7, 0.93]
10 studies · 1430 participants
Moderate
RR 0.66 [0.51, 0.85]
7 studies · 528 participants
Moderate
RR 0.97 [0.81, 1.15]
5 studies · 945 participants
High
Show 2 more findings
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific mortality ‐ SJS and TEN (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
It is very uncertain whether intravenous immunoglobulin (IVIG) changes SJS/TEN‐specific mortality (time to compared with no IVIG (very low certainty).
1 finding from 1 review
Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
1 finding from 1 review
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
1 finding from 1 review
Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) probably leads to lower incidence of CAAs (up to 30 days) compared with acetylsalicylic acid (ASA) (moderate certainty).
1 finding from 1 review
Acute coronary syndrome · people undergoing initial treatment for KD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of fever · people undergoing initial treatment for KD
1 finding from 1 review
Need for extra treatment · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) may leads to lower need for additional treatment (up to 6 months) compared with different infusion regimens of IVIG (low certainty).
1 finding from 1 review
Duration of hospital stay MCID: 1 day absolute difference · people undergoing initial treatment for KD
1 finding from 1 review
Mortality (all‐cause) (up to 7 weeks) · people undergoing initial treatment for KD
1 finding from 1 review
Incidence of CAAs (acute phase) · people undergoing initial treatment for KD
It is very uncertain whether primary treatment with intravenous immunoglobulin (IVIG) changes incidence of CAAs (acute phase) compared with prednisolone (very low certainty).
1 finding from 1 review